We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

59 hedge funds and large institutions have $234M invested in Xenon Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

189% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 9

180% more capital invested

Capital invested by funds: $83.6M → $234M (+$151M)

40% more funds holding

Funds holding: 42 → 59 (+17)

5.99% more ownership

Funds ownership: 64.37% → 70.37% (+6%)

27% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 15

Holders
59
Holders Change
+17
Holders Change %
+40.48%
% of All Funds
1.35%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.07%
New
26
Increased
11
Reduced
15
Closed
9
Calls
$6K
Puts
–
Net Calls
+$6K
Net Calls Change
+$2K

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$16.3M
2
ACA
Avoro Capital Advisors
New York
+$13.5M
3
Capital International Investors
Capital International Investors
California
+$10.9M
4
BC
Broadfin Capital
New York
+$10.4M
5
Citadel Advisors
Citadel Advisors
Florida
+$8.74M

Top Sellers

Rank Fund Capital Flow
1
Capital World Investors
Capital World Investors
California
-$5.39M
2
TCM
Tekla Capital Management
Massachusetts
-$1.51M
3
IPC
Invesco Private Capital
New York
-$1.38M
4
Deutsche Bank
Deutsche Bank
Germany
-$797K
5
SFM
Sphera Funds Management
Israel
-$690K
Name Holding Trade Value Shares
Change 		Change in
Stake
State of New Jersey Common Pension Fund D
26
State of New Jersey Common Pension Fund D
New Jersey
$2.05M – – –
IPC
27
Invesco Private Capital
New York
$1.71M -$1.38M -119,284 -48%
AGA
28
Altrinsic Global Advisors
Connecticut
$1.58M +$1.39M +120,000 New
SCM
29
Stonepine Capital Management
Oregon
$1.32M +$1.16M +100,000 New
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
$1.17M -$324K -28,000 -24%
Millennium Management
31
Millennium Management
New York
$1.09M +$960K +82,873 New
MIM
32
Monashee Investment Management
Massachusetts
$1.06M – – –
Two Sigma Investments
33
Two Sigma Investments
New York
$1.01M +$887K +76,585 New
SC
34
Scotia Capital
Ontario, Canada
$754K -$84.3K -7,271 -11%
California Public Employees Retirement System
35
California Public Employees Retirement System
California
$726K – – –
Deutsche Bank
36
Deutsche Bank
Germany
$692K -$797K -68,800 -57%
JC
37
JBF Capital
Colorado
$528K – – –
O
38
OppenheimerFunds
New York
$380K +$72.8K +6,286 +28%
NSEDCP
39
NJ State Employees Deferred Compensation Plan
New Jersey
$330K -$290K -25,000 -50%
State Street
40
State Street
Massachusetts
$257K +$226K +19,500 New
BFM
41
Boothbay Fund Management
New York
$254K -$186K -16,044 -45%
EWM
42
Elmwood Wealth Management
California
$247K -$217K -18,729 -50%
PP
43
PDT Partners
New York
$212K -$20.4K -1,763 -10%
MCM
44
Moore Capital Management
New York
$198K +$174K +15,000 New
Bank of Montreal
45
Bank of Montreal
Ontario, Canada
$155K +$110K +9,523 +433%
Walleye Trading
46
Walleye Trading
New York
$151K +$133K +11,470 New
TI
47
Trexquant Investment
Connecticut
$148K +$130K +11,198 New
AAMU
48
Amundi Asset Management US
Massachusetts
$148K +$130K +11,200 New
Dimensional Fund Advisors
49
Dimensional Fund Advisors
Texas
$147K – – –
Northern Trust
50
Northern Trust
Illinois
$136K +$119K +10,298 New
1
2
3

XENE Hedge Fund Activity: Q3 2018 in Review

59 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q3 2018, worth a combined $234M — up 180% from $83.6M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new XENE positions and 9 closed out — a net gain of 17 holders — while 11 added to existing stakes and 15 trimmed.

The largest buyer was Vivo Capital, opening a new position worth an estimated $16.3M. The largest seller was Capital World Investors, cutting an estimated $5.39M.

  • 59 institutional investors held Xenon Pharmaceuticals (XENE) as of Q3 2018, up from 42 in Q2 2018.
  • Funds reported $234M of Xenon Pharmaceuticals stock for Q3 2018, up 180% quarter-over-quarter.
  • 26 funds opened new Xenon Pharmaceuticals positions in Q3 2018 and 9 closed out, a net change of +17 holders.
  • The largest Xenon Pharmaceuticals buyer in Q3 2018 was Vivo Capital, an estimated $16.3M added.
  • The largest Xenon Pharmaceuticals seller in Q3 2018 was Capital World Investors, an estimated $5.39M sold.

Based on aggregated 13F filings for Q3 2018.